HIV Neurobehavioral Research Program (HNRP), San Diego, CA
Targeting 6 different conditionsTHC +1 morePhase 2Waitlist AvailableLed by Ronald J Ellis, MD, PhDResearch Sponsored by University of California, San Diego

Study Summary

This trial will study the effects of cannabis use and HIV on the brain and inflammation. Participants will be given the same treatment in a different order over 6 weeks to monitor safety and measure the effects of the drug.

Eligible Conditions
  • Cannabis
  • Tetrahydrocannabinol
  • Neuroinflammatory Disease
  • Neuroinflammatory Response
  • Microbiome

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have used cannabis with THC in it at least once in the past 5 years without any serious negative effects like hallucinations or fainting.
You have not used cannabis in the past 6 months, or if you have, it has been very limited, like only using it once a month.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 4 to week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week 4 to week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Secondary outcome measures
blood-brain barrier (BBB)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: THC first, then CBDExperimental Treatment2 Interventions
THC 10mg + placebo daily for 2 weeks, followed by washout for 2 weeks, followed by CBD 600mg + placebo daily for 2 weeks
Group II: CBD first, then THCActive Control2 Interventions
CBD 600mg + placebo daily for 2 weeks, followed by washout for 2 weeks, followed by THC 10mg + placebo daily for 2 weeks
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
Completed Phase 2

Find a site

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,077 Previous Clinical Trials
1,843,122 Total Patients Enrolled
Ronald J Ellis, MD, PhDPrincipal Investigator
UC San Diego
2 Previous Clinical Trials
132 Total Patients Enrolled

Media Library

CBD (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT05514899 — Phase 2
HIV/AIDS Clinical Trial 2023: CBD Highlights & Side Effects. Trial Name: NCT05514899 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still available slots for those wishing to partake in this research?

"Per the information posted on, this research is not actively recruiting participants at present. The trial was first announced October 1st 2022 and last updated September 14th of that same year. Even though this investigation has halted recruitment for now, there are still 450 other studies seeking volunteers presently."

Answered by AI

Has the Food and Drug Administration sanctioned THC for medicinal use?

"In our assessment, THC's safety was rated a 2 due to its Phase 2 trial status. This indicates that there is some information on the drug's security but none demonstrating effectiveness."

Answered by AI
~67 spots leftby Oct 2027